Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

NCT02525484
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pirfenidone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

NCT00649467
View directory record Official record
Conditions
Healthy
Interventions
Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsules 25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

NCT01870986
View directory record Official record
Conditions
Healthy
Interventions
PF-06410293, Humira (adalimumab-EU), Humira (adalimumab-US)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Participants
Interventions
Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions

NCT00652886
View directory record Official record
Conditions
To Determine the Bioequivalence Under Fasting Conditions
Interventions
Oxandrolone, Oxandrin
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2008 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions

NCT01659905
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02221180
View directory record Official record
Conditions
Bioequivalence
Interventions
Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853268
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of Ixekizumab in Healthy Participants

NCT04259346
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

NCT00835042
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/hydrochlorothiazide 15/25 mg tablets, UNIRETIC® 15/25 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

NCT01500408
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

NCT00835588
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274
View directory record Official record
Conditions
Bioequivalence
Interventions
Tacrolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

NCT00829426
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

NCT05935917
View directory record Official record
Conditions
Smallpox
Interventions
Brincidofovir
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Leflunomide 20 mg Tablets Under Fasting Conditions

NCT00834418
View directory record Official record
Conditions
Healthy
Interventions
Leflunomide 20 mg Tablets, ARAVA™ 20 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

NCT07010406
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Povetacicept
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

NCT00649935
View directory record Official record
Conditions
Healthy
Interventions
Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

NCT02019485
View directory record Official record
Conditions
Healthy
Interventions
Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF), Tapentadol Prolonged-Release Formulation 2 (PR2)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 24, 2026, 3:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)

NCT01012934
View directory record Official record
Conditions
Healthy
Interventions
Alendronate Sodium Tablets, 70 mg, Fosamax Tablets, 70 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2009 · Synced Oct 24, 2026, 3:33 PM EDT